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A b s t r a c t
Background: Tissue inhibitors of matrix metalloproteinases (TIMPs) are known to be involved in cardiovascular diseases. Hith-
erto, they have not been examined in dilated cardiomyopathy in the course of Emery-Dreifuss muscular dystrophy (EDMD).
Aim: To define TIMPs in serum because they might help in defining cardiac dysfunction at the early cardiological stages of 
this disease and detect preclinical stages of cardiomyopathy.
Methods: Twenty-five EDMD patients connected with lamin A/C (AD-EDMD) or emerin (X-EDMD) deficiency and 20 healthy 
age-matched controls were examined. The serum levels of the tissue inhibitors TIMP-1, -2, -3 were quantified using the ELISA 
sandwich immunoassay procedure with appropriate antibodies.
Results: Serum levels of TIMP-1 were normal in autosomal AD-EDMD and increased in the majority of X-linked EDMD. The 
level of TIMP-2 was decreased in 25%/21% of AD-EDMD/X-EDMD cases. TIMP-3 serum level was significantly reduced in 
all the examined patients. Receiver operating curves indicated that in terms of sensitivity and specificity characteristics the 
performance of TIMP-3 (less that of TIMP-2) makes them the best markers of cardiac involvement among the examined TIMPs.
Conclusions: Evidence shows that the levels of TIMP-3, and in some cases also TIMP-2, are decreased in EDMD. The decrease 
might be associated with an adverse effect on matrix metalloproteinases and remodelling of the myocardial matrix. The specific 
decrease of TIMP-3 indicates that this biomarker might help in early detection of cardiac involvement in EDMD. Up-regulation 
of TIMP-1 in the majority of patients with X-EDMD indicates increased myocardial extracellular matrix turnover, early onset 
of tissue remodelling, and may contribute to arrhythmia, frequently occurring in this form of the disease.
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INTRODUCTION
Emery-Dreifuss muscular dystrophy (EDMD) is a rare, geneti-
cally transmitted disease, which is associated with a defect in 
EMD or LMNA genes encoding nuclear proteins: emerin or 
lamin A/C, respectively. EDMD associated with emerinopathy 
is known as X-EDMD (X-linked EDMD), while that associated 
with laminopathy is known as AD-EDMD (autosomal domi-
nant EDMD). The clinical symptoms are manifested as skeletal 
muscle atrophy and weakness, joint contractures, and dilated 
cardiomyopathy (DCM) with conduction defects [1]. While 
the latter often remains clinically silent for prolonged periods, 
sudden death is not a rare event. The pathogenesis of DCM 
in EDMD is not recognised, yet. It is supposed that changes 
in the myocardial extracellular matrix (ECM), important for 
ventricular stability and alignment of cardiomyocytes [2], are 
responsible for the induction of matrix metalloproteinases 
www.kardiologiapolska.pl
TIMPs in serum are cardiac biomarkers in Emery-Dreifuss muscular dystrophy
361
(MMPs) connected with a decrease in levels of tissue inhibi-
tors of matrix metalloproteinases (TIMPs). Potentially it may 
evoke DCM [3–7]. In EDMD changed values of MMPs are 
observed  [8]. They indicate cardiac involvement and help 
monitoring of the DCM treatment.
Tissue inhibitors of metalloproteinases 1-4 (TIMP-1-4) are 
endogenous regulators of MMPs. They participate in cellular 
homeostasis, tissue remodelling, and adaptation. TIMPs influ-
ence cardiac fibroblasts, endothelial cells, cardiomyocytes, 
smooth muscle cells, and inflammatory cells, promote cell 
growth, and have antiapoptotic and anti-androgenic activity, 
and provide means of negatively controlling tissue effects of 
MMPs [9–11]. Changes in TIMPs are associated with heart 
failure. An imbalance between MMPs and TIMPs is seen in 
tissue destruction and degradation of ECM structural pro-
teins. MMPs also play a role in left ventricular (LV) structural 
remodelling [12]. The imbalance between MMPs and TIMPs 
may contribute to the risk of arrhythmia and atrial fibrillation 
[13]. Plasma TIMPs are associated with major cardiovascular 
risk and indicate LV hypertrophy, systolic dysfunction, and in-
creased mortality in congestive heart failure [14, 15]. In failing 
hearts MMP/TIMP production is dysregulated, and elevated 
TIMP content may represent a compensatory response to 
increased MMP activity [16].
The aim of this study was to define the value of TIMPs 
in serum of EDMD patients because this might identify the 
cardiac status in EDMD. This is because there is the pos-
sibility of unexpected cardiac decompensation and a risk of 
sudden death, even in young patients. Until now there were 
no available data on the level of circulating TIMPs in EDMD.
METHODS
Patient characteristics
A total of 25 young patients (19 males and 6 females) with 
EDMD were included. Ten patients had AD-EDMD and 
15 had X-EDMD. Twenty age-matched healthy controls with 
no history of cardiac and skeletal muscle symptoms were 
examined as controls.
Initial diagnosis in these patients was based on the 
clinical status, blood creatine kinase activity, immunohis-
tochemistry, electron microscopy, and electromyography. It 
was finally confirmed by LMNA and EMD gene screening. 
Cardiac disease was diagnosed in all patients (Table 1). In the 
AD-EDMD patients the progression of cardiological symptoms 
ranged from mild/moderate to severe/very severe. Conduc-
tion defect or impaired contractility was seen. A pacemaker 
had been implanted in five of the AD-EDMD patients, and 
a cardioverter-defibrillator in two other cases. One patient 
underwent heart transplantation and one patient suddenly 
died. In ten X-EDMD patients the cardiac involvement was 
either moderate or mild; in one case it was severe. Among the 
cardiac parameters conduction defects and atrial involvement 
predominated. In the majority of them (12/15) a pacemaker 
had been implanted. In neither of the EDMD groups was it 
a straightforward matter to track the development of cardio-
myopathy. Even patients with evident bradycardia had usually 
had their cardiac symptoms detected once the first neurologi-
cal diagnosis of EDMD had been established. Skeletal muscle 
atrophy was diagnosed in all patients (Table 1). In AD-EDMD 
it was mild in two cases, moderate in four, and severe/very 
severe in the remaining four. In X-EDMD skeletal muscle 
atrophy was present in 12 cases, being either mild/moderate 
or severe in three cases.
Biochemical analysis
Blood was collected for routine biochemical analyses and 
centrifuged at 3000 rpm for 10 min. Serum was separated 
and frozen at –30°C until used. The levels of the biomarkers 
were determined using an ELISA-based one-step sandwich 
enzyme immunoreaction for TIMP-1 and TIMP-2 using human 
immunoassay kits (with anti-TIMP-1 or anti-TIMP-2 coated 
microplate, Chemicon Intern). To test TIMP-3 a DuoSet ELISA 
Development Systems with biotinylated mouse anti-human 
TIMP-3 (R&D) was used. The absorbance at 450 nm was then 
assessed using a Sigma Diagnostics EIA Microwell Reader II 
(Hercules, CA, USA).
Statistical analysis
Analyses were performed using a statistical software STATISTICA 
version 9.0 (StatSoft, Inc. Poland). The means and standard 
errors are presented. The analysis of variance on ranks with 
the Kruskal-Wallis test was done. Differences in variable values 
were assessed using the Mann-Whithney U test, while the 
relationships between variables were analysed using Spear-
man’s correlation (r). The receiver operating curves (ROC) 
analysis, providing an index of accuracy and discrimination 
between normal state and probability of disease in individual 
subjects, was also included [17, 18]. A p value < 0.05 value 
was considered statistically significant.
RESULTS
The analysis of TIMP-1 in the serum of the EDMD patients 
showed that the level was changed in 13% of AD-EDMD 
patients and in 71% of the X-EDMD cases. TIMP-2 was in turn 
significantly decreased in 25% of patients with AD-EDMD 
form and 21% of the X-EDMD patients. TIMP-3 was signifi-
cantly lower in all EDMD cases than in the controls (Table 2). 
The TIMP values were compared to those of tenascin C 
(TN-C), creatine kinase isoenzyme MB (CK-MB), atrial 
natriuretic peptide (ANP), B-type natriuretic peptide (BNP), 
N-terminal prohormone of BNP (NT-proBNP), and MMPs, 
which were examined using the same serum samples and 
summarised in our previous paper [8]. There was a significant 
correlation in X-EDMD between TIMP-1, TN-C (r = –0.64, 
p < 0.018), and CK-MB (r = 0.64, p < 0.024). In AD-EDMD 
there was a correlation between TIMP-1 and NT-proBNP 
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(r = 0.86, p < 0.014). A significant correlation in X-EDMD 
between TIMP-3, BNP (r = –0.62, p < 0.022), and ANP 
(r = –0.72, p < 0.012) was present. In AD-EDMD there 
was a significant correlation between TIMP-3 and membrane 
type 1 MMP (MT1-MMP) (r = –0.83, p < 0.042). To assess 
the value of TIMP estimation for the EDMD diagnosis, the 
area under the receiver operating curves (AUC of ROC) was 
calculated (Fig. 1). In terms of sensitivity and specificity in 
the ROC characteristics the performance of TIMP-3 and 
of TIMP-2 made TIMP-3 the best marker from the TIMPs 
set (AUC = 0.989 for TIMP-3, AUC = 0.923 for TIMP-2, 
AUC = 0.758 for TIMP-1).
Table 1. Clinical and laboratory data in patients with Emery-Dreifuss muscular dystrophy (EDMD)
Description X-EDMD (n = 15) AD-EDMD (n = 10)




Age [years] 28 ± 12 30 ± 11
Skeletal muscle involvement Elbow, ankle contractures, and spine rigidity (15)
Generalised muscle atrophy (3)
Arms, calf atrophy (5)
Arm atrophy (2)
Elbow, ankle contractures, and spine rigidity (9)
Generalised atrophy (6)
Arms, thighs (2)
Arms, calf atrophy (1)
Wheelchair-bound (2)









Cardiac device/age of implantation Pacemaker/14–33 years (11) Pacemaker/20–41 years (5),  
















Number of patients is shown in parentheses. AF —  atrial fibrillation; AFL — atrial flutter; AVB — atrio-ventricular block; ICD — implanted 
cardioverter-defibrillator; NYHA — New York Heart Association; SVT — supraventricular tachycardia; VT — ventricular tachycardia
























Values are means ± standard errors; *p < 0.005 for patients vs. controls; #p < 0.002 for AD-EDMD vs. X-EDMD patients; aChanged values vs. 
controls: increased (i) or decreased (d)
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DISCUSSION
Most studies devoted to TIMPs in cardiac pathology have 
concerned DCM [19], congestive heart failure [16], acute 
myocardial infarction (MI) [20–22], and LV diastolic dysfunc-
tion and fibrosis in hypertension [23]. The common feature 
of above-mentioned pathologies is myocardial tissue remod-
elling of ECM and fibrosis as a consequence of biochemical 
stress [24], leading to ventricle dilatation and contractile 
dysfunction. The balance between MMPs, which degrades 
ECM and TIMPs, is responsible for ECM turnover. There have 
been no reports on TIMPs in heart disease in patients with 
EDMD. In our study we analysed the serum levels of TIMP-1, 
TIMP-2, and TIMP-3. We found changed TIMP-1 in 13% of 
AD-EDMD and in 71% of the X-EDMD patients. TIMP-1 is an 
independent predictor of cardiovascular mortality and stroke 
[25] and of non-response in patients treated with cardiac re-
synchronisation therapy [26]. An increase level of TIMP-1 was 
found in the acute phase of MI [20], in hypertension, and in 
diastolic dysfunction [23], indicating an early activation of the 
MMP/TIMP system in the myocardium. However, in ischaemic 
and dilated cardiomyopathy, cardiac expression of TIMP-1 on 
the mRNA and protein level was significantly reduced [16].
TIMP-2 was in turn significantly decreased in 25% of 
patients with AD-EDMD form and in 21% of the X-EDMD 
patients. Apart from inhibition of MMPs, TIMP-2 in the heart 
is required for cell-surface activation of MMP-2 (pro-MMP2). 
TIMP-2 is unique among TIMPs because, as well as inhibiting 
a number of MMPs, it also causes MMP-2 activation by inter-
acting with MT1-MMP and pro-MMP, forming a tri-molecular 
complex [27, 28]. Lack of TIMP-2 leads to exacerbated LV 
dysfunction and adverse remodelling of ECM in response to 
biochemical stress after pressure overload [24]. TIMP-2 is 
altered in different heart diseases such as hypertension and 
atrial fibrillation. In the end-stage of DCM TIMP-2 is unaltered 
or increased; it is also raised in late stages of MI [3]. The inhibi-
tory function of TIMP-2 on MT1-MMP is a key determinant 
of remodelling after MI. TIMP-2 deficiency increases the 
severity of the disease after MI: it increases LV dilatation and 
induces excess degradation of ECM collagen and enhanced 
inflammation [24].
In our analysis in patients with EDMD we found a sig-
nificant decrease of TIMP-3 in both groups: X-EDMD and 
AD-EDMD. This observation is consistent with reports of other 
authors, i.e. Li et al. [16], who found significant reduction of 
TIMP-3 expression on RNA and protein levels in the failing 
human heart. Also, Fedak et al. [19] found that TIMP-3 defi-
ciency triggered spontaneous dilatation of LV, cardiomyocyte 
hypertrophy, and contractile dysfunction, consistent with hu-
man DCM. TIMP-3 differs from the other TIMPs in its direct 
binding with ECM components, and it models MMPs activity 
better than the other TIMPs. It is highly expressed in the 
heart and probably takes part in ECM embryonal remodel-
ling and heart development. Reductions in TIMP-3 parallel 
adverse matrix remodelling in cardiomyopathic hamsters and 
failing human heart. TIMP-3 contributes to the regulation of 
remodelling in the myocardium, and its reduction is capable 
of promoting a transition from compensated to end-stage 
congestive heart failure through matrix degradation and 
cytokine activation. TIMP-3 deficiency impairs LV function, 
alters cardiac structure, and disrupts matrix homeostasis and 
the balance between inflammatory mediators, leading to car-
diac dilatation and dysfunction [19]. TIMP-3 is critical during 
the early stages of recovery from MI. It is a novel marker for 
risk stratification in non-ischaemic cardiomyopathy. Reduced 
TIMP-3 levels in hearts with ischaemic cardiomyopathy, when 
over-expressed or supplemented with TIMP-3, may prove 
to be a therapeutic approach. Therapeutic restoration of 
myocardial TIMP-3 in patients with DCM may limit cardiac 
remodelling and progression to heart failure and may prove 
to be a therapeutic approach.
CONCLUSIONS
In the presented study we have provided evidence for TIMP 
behaviour in DCM in EDMD. No data in the literature are 
available at present. Abnormalities in TIMPs in EDMD have 
already been suggested in previously published results on 
increased activity of MMPs, which might indicate decreases 
in the action of TIMPs [28]. In the analysed group of patients 
with both types of EDMD we observed a significant decrease 
Figure 1. The receiver operating curves (ROC) for tissue inhi-
bitors of matrix metalloproteinases (TIMPs) in Emery-Dreifuss 
muscular dystrophy patients; AUC — area under the ROC
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in TIMP-3. This might promote a transition from compensated 
to end-stage cardiomyopathy, and may be associated with 
adverse remodelling of the myocardial matrix. Therefore, 
the serum level of TIMP-3 might be a candidate biomarker 
of cardiac involvement in EDMD, especially in early cardiac 
asymptomatic patients. Reduction in TIMP-2, and changes 
in TIMP-1, although found in a smaller number of patients, 
could indicated an imbalance between TIMPs and MMPs, 
which disturbs the architecture of the ECM and contributes 
to LV remodelling and the subsequent deterioration of LV 
performance. On the other hand, up-regulation of TIMP-1, 
present in the majority of patients with X-EDMD, might suggest 
an increased ECM turnover and early onset of tissue remodel-
ling and may contribute to arrhythmia, frequently occurring 
in this form of EDMD.
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S t r e s z c z e n i e
Wstęp: Tkankowe inhibitory metaloproteinaz macierzy (TIMPs) są zaangażowane w patogenezę chorób układu sercowo-
-naczyniowego. Dotychczas nie badano stężenia TIMPs u pacjentów z kardiomiopatią rozstrzeniową w przebiegu dystrofii 
mięśniowej Emery’ego-Dreifussa (EDMD).
Cel: Celem badania było określenie stężenia TIMPs w surowicy pacjentów z EDMD w celu rozstrzygnięcia, czy mogłyby 
stanowić biomarker dysfunkcji mięśnia sercowego na wczesnych etapach choroby i pomóc w wykrywaniu kardiomiopatii 
w okresie przedklinicznym.
Metody: Zbadano 25 pacjentów z EDMD związaną z mutacją w genie laminy A/C (AD-EDMD) lub w genie emeryny  
(X-EDMD) oraz 20 zdrowych osób z grupy kontrolnej, dobranych pod względem wieku. Stężenia TIMP-1, -2, -3 w surowicy 
określono za pomocą testu immunoenzymatycznego ELISA z odpowiednimi przeciwciałami.
Wyniki: Stężenia TIMP-1 w surowicy były prawidłowe u chorych z AD-EDMD, a zwiększone u większości pacjentów  
z X-EDMD. Stężenie TIMP-2 w surowicy było obniżone u 25% i /21% chorych, odpowiednio, z AD-EDMD i X-EDMD. Stężenie 
TIMP-3 było znamiennie obniżone u wszystkich badanych pacjentów. Krzywe ROC wskazywały, że spośród wszystkich zba-
danych TIMPs pod względem czułości i specyficzności TIMP-3 (a w mniejszym stopniu TIMP-2) jest najlepszym biomarkerem 
uszkodzenia mięśnia sercowego u chorych z EDMD.
Wnioski: Uzyskane wyniki wskazują, że u chorych z EDMD stężenia TIMP-3 w surowicy, a w niektórych przypadkach także 
TIMP-2, są obniżone. Obserwowany spadek może się wiązać z niekorzystnym wpływem na metaloproteinazy macierzy oraz 
remodelowaniem macierzy miokardium. Specyficzny spadek stężenia TIMP-3 w surowicy chorych wskazuje, że biomarker 
ten mógłby być użyteczny we wczesnej detekcji zajęcia mięśnia sercowego w EDMD. Regulacja w górę TIMP-1 u większości 
pacjentów z X-EDMD wskazuje na zwiększony obrót macierzy zewnątrzkomórkowej, zaś obserwowane remodelowanie tkanki 
może uczestniczyć w rozwoju zaburzeń rytmu serca, często stwierdzanych w tej postaci choroby.
Słowa kluczowe: dystrofia mięśniowa Emery’ego-Dreifussa (EDMD), tkankowe inhibitory metaloproteinaz macierzy (TIMPs), 
kardiomiopatia rozstrzeniowa
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